Capstone Therapeutics Corp (CAPS) financial statements (2022 and earlier)

Company profile

Business Address 1275 WEST WASHINGTON STREET
TEMPE, AZ 85281
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,3411,2756981,0112,1646,258
Cash and cash equivalents1,3411,2756981,0112,1646,258
Other current assets9798131247555233
Total current assets:1,4381,3738291,2582,7196,491
Noncurrent Assets
Property, plant and equipment     3
Long-term investments and receivables    6,0006,000
Long-term investments    6,0006,000
Intangible assets, net (including goodwill)39196353509666823
Intangible assets, net (excluding goodwill)39196353509666823
Other undisclosed noncurrent assets    (6,000)(6,000)
Total noncurrent assets:39196353509666826
TOTAL ASSETS:1,4771,5691,1821,7673,3857,317
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities246199304261282100
Accounts payable24519724925412488
Accrued liabilities1255715812
Total current liabilities:246199304261282100
Noncurrent Liabilities
Long-term debt and lease obligation2,4752,2491,0001,000  
Long-term debt, excluding current maturities2,4752,2491,0001,000  
Total noncurrent liabilities:2,4752,2491,0001,000  
Total liabilities:2,7212,4481,3041,261282100
Stockholders' equity
Stockholders' equity attributable to parent(1,244)(879)(122)5063,1037,217
Common stock272720202020
Additional paid in capital190,483190,468189,477189,442189,268189,215
Accumulated deficit(191,754)(191,374)(189,619)(188,956)(186,185)(182,018)
Total stockholders' equity:(1,244)(879)(122)5063,1037,217
TOTAL LIABILITIES AND EQUITY:1,4771,5691,1821,7673,3857,317

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues(2,000)     
Gross profit:(2,000)     
Operating expenses(2,181)(1,680)(1,584)(2,939)(4,524)(4,293)
Other undisclosed operating income4,362     
Operating income (loss):181(1,680)(1,584)(2,939)(4,524)(4,293)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
251(111)(81)(24)  
Income (loss) from continuing operations before equity method investments, income taxes:432(1,791)(1,665)(2,963)(4,524)(4,293)
Other undisclosed income (loss) from continuing operations before income taxes    (43)158
Income (loss) from continuing operations before income taxes:432(1,791)(1,665)(2,963)(4,567)(4,135)
Income tax expense (benefit)(52)365619240021
Net income (loss):380(1,755)(1,609)(2,771)(4,167)(4,114)
Net income attributable to noncontrolling interest  946  193
Net income (loss) available to common stockholders, diluted:380(1,755)(663)(2,771)(4,167)(3,921)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):380(1,755)(1,609)(2,771)(4,167)(4,114)
Comprehensive income (loss):380(1,755)(1,609)(2,771)(4,167)(4,114)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest  946  (193)
Comprehensive income (loss), net of tax, attributable to parent:380(1,755)(663)(2,771)(4,167)(4,307)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: